Clinical trials: Clopidogrel
Stable Angina, Unstable Angina
Harmonizing Optimal Strategy for Treatment of Coronary Artery Stenosis - Coronary Intervention With Next Generation Drug-Eluting Stent Platforms and Abbreviated Dual Antiplatelet Therapy (HOST-IDEA) Trial
We had little experience in coronary intervention with recently introduced newer drug-eluting stent (DES) platforms, despite great anticipation, and optimal duration of dual antiplatelet therapy (DAPT) for these stent systems…
- Conditions
- Stable Angina, Unstable Angina, Non-ST Segment Elevation Myocardial Infarction
- Trial name
- HOST-IDEA (NCT02601157)
- Testing
- 3-months DAPT, 1-year DAPT
- Where
- 12 sites in South Korea
- Volunteers
- 2,173 people
- Sponsor
- Seoul National University Hospital
Platelet Reactivity
Platelet Function Monitoring in Patients Treated With Clopidogrel at the Time of Primary Percutaneous Coronary Angioplasty
Platelets are a major component of clot formation which can lead to clotting events such as heart attack. During treatment for a heart attack, doctors try to remove this blockage as quickly as possible so that the heart can…
- Trial name
- NCT00827346
- Testing
- Clopidogrel
- Where
- Canada
- Volunteers
- 100 people
- Sponsor
- Ottawa Heart Institute Research Corporation
Acute Coronary Syndrome, Myocardial Infarction
Outcome of Longterm Antithrombotic Therapy in Acute Coronary Syndrome Patients
This observational study will based on the Register of Information and Knowledge About Swedish Heart Intensive Care Admissions (RIKS-HIA) and the Swedish Coronary Angiography and Angioplasty Registry (SCAAR) which since 2009 are…
- Trial name
- NCT01623700
- Where
- Sweden
- Volunteers
- 78,000 people
- Sponsor
- Uppsala University
Mitral Regurgitation
STrategies for Antithrombotic tReatment Following Transcatheter Edge-to-Edge Repair in Patients Without an Indication for Oral Anticoagulant
Mitral regurgitation (MR) is the most common valvular heart disease, affecting approximately 24.2 million people worldwide (with a higher prevalence in older age groups).
- Trial name
- STAR-TEER Ⅱ (NCT07007143)
- Testing
- Experimental: Aspirin monotherapy, Active Comparator: Aspirin+Clopidogrel
- Where
- China
- Volunteers
- 1,032 people
- Sponsor
- Chinese Academy of Medical Sciences, Fuwai Hospital
Heart Defects, Congenital
Long Term Safety of Clopidogrel in Neonates/Infants With Systemic to Pulmonary Artery Shunt Palliation
This study is the extension of the CLARINET study [NCT00396877 -EFC5314] in neonates or infants with cyanotic congenital heart disease palliated with a systemic-to-pulmonary artery shunt.
- Trial name
- CLARINET LT (NCT00833703)
- Testing
- Clopidogrel
- Where
- 15 sites in United States, Brazil and 13 more
- Volunteers
- 49 people
- Sponsor
- Sanofi
Coronary Heart Disease, Acute Coronary Syndrome
Cohort Study of Clopidogrel and Proton Pump Inhibitors
Patients who have experienced and survived non-ST segment elevation acute coronary syndromes are often prescribed a combination of aspirin and clopidogrel to thin the blood and prevent further acute coronary episodes.
- Conditions
- Coronary Heart Disease, Acute Coronary Syndrome, Drug Interactions, Clopidogrel
- Trial name
- NCT01231867
- Where
- United Kingdom
- Volunteers
- 24,471 people
- Sponsor
- London School of Hygiene and Tropical Medicine
Stable Angina, Unstable Angina, Silent Coronary Ischemia, Coronary Artery Disease
ISAR-DAPT (A Comparative Evaluation of Efficacy and Safety in the 3-Months DAPT Group vs. the 6-Months DAPT Group of Patients Treated With the Coroflex ISAR Stent; A Prospective, Multicenter, Randomized, Open-Label Clinical Trial)
This clinical trial studies patients treated with the Coroflex ISAR Stent for coronary artery disease in order for the objective of verifying the non-inferiority of results that among patients who were administered DAPT for 3…
- Trial name
- NCT02609698
- Testing
- Coroflex ISAR, 3 months DAPT, 6 months DAPT
- Where
- South Korea
- Volunteers
- 906 people
- Sponsor
- Ajou University School of Medicine
Coronary Artery Disease
(EASY)-IMProving Adherence to Clopidogrel Trial (IMPACT))
The purpose of this study is to test the impact of a multidisciplinary approach to improve the adhesion and persistence to Clopidogrel therapy.
- Trial name
- EASY-IMPACT (NCT01134679)
- Testing
- Multi-disciplinary disease management approach
- Where
- Canada
- Volunteers
- 300 people
- Sponsor
- Laval University
Myocardial Infarction, Myocardial Fibrosis
Modulation of Fibrosis-inducing Pathways in Acute Myocardial Infarction
This is a single-center, prospective, observational controlled cohort study designed to describe the role of WNT/B-catenin signaling and adenosine system after an acute myocardial infarction, correlating it with clinical markers…
- Conditions
- Myocardial Infarction, Myocardial Fibrosis, Myocardial Remodeling, Ventricular
- Trial name
- BETA-MI (NCT05122741)
- Testing
- P2Y12 Potent Inhibitor + Aspirin for STEMI patients, Clopidogrel + Aspirin for CCS patients
- Where
- Italy
- Volunteers
- 50 people
- Sponsor
- University of Messina
Coronary Disease, Heart Diseases
Single vs. Dual Antiplatelet Therapy in Elderly or HBR Patients Undergoing Percutaneous Intervention With DCB (PICCOLETO IV-EPIC 38)
This international, multicenter, open-label, randomized clinical trial evaluates the safety and efficacy of single antiplatelet therapy (SAPT) compared to dual antiplatelet therapy (DAPT) in elderly or high bleeding risk patients…
- Conditions
- Coronary Disease, Heart Diseases, Cardiovascular Diseases, Myocardial Ischemia
- Trial name
- PIV-EPIC (NCT06535568)
- Testing
- Drug-coated balloon, Single antiplatelet therapy (SAPT), Dual antiplatelet therapy (DAPT)
- Where
- Italy
- Volunteers
- 576 people
- Sponsor
- Fondazione Ricerca e Innovazione Cardiovascolare ETS
Coronary Heart Disease, Percutaneous Coronary Intervention
Comparison of Generic and Original Formulation of Clopidogrel
Clopidogrel is essential for the prevention of vascular events in patients after percutaneous coronary interventions (PCI). Most of our current knowledge with clopidogrel originates from the clinical investigations that had used…
- Trial name
- DOSER-GENERIC (NCT01147133)
- Testing
- Plavix, Kardogrel
- Volunteers
- 75 people
- Sponsor
- University of Pecs
Congenital Heart Defects, Blood Platelet Disorders
Platelet Aggregation Inhibition in Children on Clopidogrel (PICOLO)
PICOLO is a double blind placebo controlled phase II dose ranging, dose escalating study in patients of Blalock-Taussig age categories (neonates and infants/toddlers), to determine the dose providing inhibition of platelet…
- Trial name
- NCT00115375
- Testing
- Clopidogrel (SR25990)
- Where
- 6 sites in United States, Belgium and 4 more
- Volunteers
- 92 people
- Sponsor
- Sanofi
Coronary Artery Disease
Pharmacodynamic Effects of Ranolazine Versus Amlodipine on Platelet Reactivity
No previous study has assessed the potential of ranolazine to interfere with levels of platelet reactivity in patients with coronary artery disease who are treated with dual antiplatelet therapy.
- Trial name
- ROMAN (NCT01490255)
- Testing
- Ranolazine, Amlodipine
- Where
- 2 sites in Italy
- Volunteers
- 100 people
- Sponsor
- University of Roma La Sapienza
Coronary Artery Disease
Different Regimen of Aprotinine(Trasylol) Administration in Patients Receiving Antiplatelet Therapy With Clopidogrel (Plavix)
Clopidogrel (Plavix), a platelet ADP receptor antagonist, has become the standard of care to prevent thrombosis in interventional cardiology and is increasingly being used in unstable angina and NSTEMI.
- Trial name
- NCT00257751
- Testing
- Aprotinine
- Volunteers
- 400 people
- Sponsor
- Oslo University Hospital
Acute Coronary Syndrome, Platelet Function
Sampling P2Y12 Receptor Inhibition With Prasugrel and Ticagrelor in Patients Submitted to Thrombolysis
Introduction: Platelet aggregation plays an important role in ischemic complications in patients undergoing to percutaneous coronary intervention (PCI).
- Trial name
- SAMPA (NCT02215993)
- Testing
- Prasugrel, Ticagrelor
- Where
- Brazil
- Volunteers
- 50 people
- Sponsor
- Federal University of São Paulo
Heart Defects, Congenital
Efficacy And Safety Of Clopidogrel In Neonates /Infants With Systemic To Pulmonary Artery Shunt Palliation
Contemporary management of cyanotic congenital heart disease includes three stages of surgery. Incidence of shunt thrombosis and death between the two first stages of palliation remains important.
- Trial name
- CLARINET (NCT00396877)
- Testing
- Clopidogrel (SR25990)
- Where
- 31 sites in United States, Argentina and 29 more
- Volunteers
- 906 people
- Sponsor
- Sanofi
Transient Ischemic Attacks, Minor Stroke
The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack
The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and…
- Trial name
- MENA-TIA (NCT02144831)
- Testing
- anti-thrombotic treatment using Aspirin (ASA 75-325mg) and Clopidogrel (75mg)
- Where
- Canada
- Sponsor
- University of Alberta
Coronary Artery Disease
Clopidogrel High Dose Evaluation for the Patient With Coronary Artery Disease in Japan
The purpose of this study is to evaluate the effect of high dose clopidogrel as the antiplatelet therapy on inhibition of platelet aggregation in Japanese patients scheduled for percutaneous coronary intervention due to ischemic…
- Trial name
- CHOICE (NCT01069302)
- Testing
- Clopidogrel
- Where
- Japan
- Volunteers
- 106 people
- Sponsor
- Takeshi Morimoto
Smoking Status, Genetic Risk Factors
Effect of Smoking Status and Genetic Risk Factors on Restenosis and Efficacy of Clopidogrel After de Novo Percutaneous Coronary Intervention
Restenosis occurs for many different reasons. Over the years, many predictive clinical, biological, genetic, epigenetic, lesion-related, and procedural risk factors for restenosis have been identified.
- Conditions
- Smoking Status, Genetic Risk Factors, Restenosis, Clopidogrel
- Trial name
- NCT03613337
- Testing
- clinical restenosis
- Where
- China
- Volunteers
- 120 people
- Sponsor
- Cui Yimin
Coronary Artery Disease
Resistance on Antithrombotic Drugs in Ischemic Heart Disease
The purpose of this study is to determine whether aspirin and clopidogrel resistance measured with Multiplate function analyser has a good correlation with incidence of major adverse cardiac events in patients with coronary…
- Trial name
- NCT00742430
- Testing
- PCI
- Where
- Croatia
- Volunteers
- 141 people
- Sponsor
- University of Zagreb